|
INCREASED SEDATIVE EFFECT
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
INCREASED SEDATIVE EFFECT
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
INCREASED SEDATIVE EFFECT
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
INCREASED SEDATIVE EFFECT
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
OPIOD ANALGESICS IN HIGH DOSE MAY RESULT IN DROP IN HEART RATE AND CARDIAC OUTPUT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
INCREASED SEDATIVE EFFECT
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT; BUT RATE OF ORAL ABSORPTION OF DIAZEPAM IS REDUCED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
INCREASED ANALGESIC EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|